Recently added

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA

Tibau Martorell, Ariadna; Hwang, Thomas; Romano Cardozo, Alejandra; Borrell, Maria; Molto Valiente, Consolacion; Gich, Ignasi (American Medical Association, 2025-03)

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study

Magaton, Isotta; Linn, Sabine; peccatori, fedro; Blondeaux, Eva; HAMY, Anne-Sophie; Bernstein Molho, Rinat; Carrasco Lopez, Estela (Elsevier, 2025-06-03)

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth

Guerrero, Mario; PROAÑO PEREZ, ELIZABETH; Serrano Candelas, Eva; García-Valverde, Alfonso; Carrillo Rodriguez, Berenice; Rosell, Jordi; Serrano, Cesar (Elsevier, 2025-06-18)

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

Driemel, Christiane; Shen, Lin; Chung, Hyun Cheol; Cannon, Timothy; André, Thierry; GARRALDA, Elena (Elsevier, 2025-05-02)

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

Aroldi, Francesca; Elez, Elena; Perkins, Géraldine; Popovici, Vlad; André, Thierry; Prenen, Hans; Tabernero, Josep (BMC, 2025-04-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA ﻿

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study ﻿

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth ﻿

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer ﻿

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) ﻿

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)